|
Apr 5
|
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
|
|
Apr 1
|
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
|
|
Mar 20
|
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
|
|
Mar 15
|
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
|
|
Mar 7
|
Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term
|
|
Mar 6
|
When Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit?
|
|
Mar 5
|
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
|
|
Dec 6
|
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
|
|
Aug 8
|
2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023
|
|
Feb 10
|
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
|